Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), is spectrum of diseases that ranges from non-alcoholic fatty liver (NAFL) to ...
Use of the long-acting FGF21 analog efruxifermin led to statistically significant improvements in fibrosis and resolution of nonalcoholic steatohepatitis (NASH) compared with placebo, the phase IIb ...
Please provide your email address to receive an email when new articles are posted on . Both 80 mg and 100 mg doses of resmetirom achieved liver biopsy endpoints at 52 weeks in patients with ...
Shares of 89bio ETNB were up 25.2% on Mar 22 after management reported positive data from the phase IIb ENLIVEN study which is evaluating its lead candidate, pegozafermin, in patients with ...
Metabolic dysfunction-associated steatohepatitis (MASH), previously called nonalcoholic steatohepatitis (NASH), is a more severe form of fatty liver disease that causes inflammation and damage. MASH ...
April 25 (Reuters) - Gilead Sciences Inc said on Thursday its experimental drug to treat scarring of tissue due to nonalcoholic steatohepatitis (NASH) did not meet main goal of a late stage trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results